Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773857 | 1.00 | NR4A2 (0.56) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL23526183 | 0.90 | TSHR (0.52) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL6072552 | 0.90 | ALDH1A1 (0.54) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL24252797 | 0.90 | TSHR (0.52) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL16961315 | 0.90 | NR4A2 (0.51) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL6072149 | 0.90 | ALDH1A1 (0.54) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL7370270 | 0.89 | DGAT1 (0.53) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL6071892 | 0.87 | NR4A2 (0.49) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL6072378 | 0.87 | NR4A2 (0.49) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL861495 | 0.86 | PTPN2 (0.54) | NR4A2GAAALDH1A1L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081801-A | Tetracarboxylic acid organic ligand based on benzothiadiazole functional group for preparing metal organic framework, and preparation method and application thereof | 江西理工大学 | 2025-06-03 | — | — | CN | claimed |
| CN-118082333-A | Multilayer antibacterial SPC board and preparation process thereof | 福建福晟新材料科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117486843-A | Preparation method of 3,3', 4' -biphenyl tetracarboxylic dianhydride | 大连理工大学 | 2024-02-02 | — | — | CN | claimed |
| EP-2617471-B1 | FIRE EXTINGUISHING COMPOSITION GENERATING FIRE EXTINGUISHING SUBSTANCE BY HIGH TEMPERATURE SUBLIMATION | XIAN WESTPEACE FIRE TECH CO LTD (CN) | 2018-12-12 | — | — | EP | claimed |
| US-8865014-B2 | Fire extinguishing composition generating fire extinguishing substance by high temperature sublimation | XI'AN J&R FIRE FIGHTING EQUIPMENT CO., LTD. (CN) | 2014-10-21 | — | — | US | claimed |
| EP-2617471-A1 | FIRE EXTINGUISHING COMPOSITION PRODUCING FIRE EXTINGUISHING SUBSTANCE BY HIGH TEMPERATURE SUBLIMATION | Shaanxi J&R Fire Fighting Co., Ltd. (CN) | 2013-07-24 | — | — | EP | claimed |
| US-20130168593-A1 | FIRE EXTINGUISHING COMPOSITION GENERATING FIRE EXTINGUISHING SUBSTANCE BY HIGH TEMPERATURE SUBLIMATION | SHAANXI J&R FIRE FIGHTING CO., LTD. (CN) | 2013-07-04 | — | — | US | claimed |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| WO-1999065877-A1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| US-5968908-A | Restricted 9-cis retinoids | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5880309-A | DIALKYL DIALKOXYCARBONYLPHENYL PHOSPHONATES USEFUL AS RESIN MODIFIERS PRODUCED AT HIGH YIELD AND LOW COST BY HEATING A TRIALKYL PHOSPHITE AND A DIALKOXYCARBONYLPHENYL HALIDE IN THE PRESENCE OF A PALLADIUM OR NICKEL CATALYST AND HYDROLYZING | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0855400-A1 | Phenylphosphonic acid derivative and production process therefor | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| CN-1174833-A | Phenyl substituted alkenocarboxylic guanidine, preparation method, application as medicine or diagnostic agent adn medicine containing it | HOECHST AG (DE) | 1998-03-04 | — | — | CN | disclosed |
| EP-0825178-A1 | Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or in diagnostic agents and drugs containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-25 | — | — | EP | disclosed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | NR4A2 1527/4885GAA 2330/4885ALDH1A1 2038/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | NR4A2 240/4885GAA 3090/4885ALDH1A1 4483/4885 |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | NR4A2 2701/4885GAA 4600/4885ALDH1A1 3584/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | NR4A2 2812/4885GAA 2087/4885ALDH1A1 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.